Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 7/20 | 0.42 |
| ▸ | GIPR | P48546 | 4/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.35 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18974602 | 0.91 | PTGDR2 (0.42) | PTGDR2GCGRGIPRSCN9ACACNA1B | |
| SCHEMBL18974385 | 0.91 | CNR1 (0.38) | SCN9ATRPM8CCR5STSCYP19A1 | |
| SCHEMBL18974618 | 0.90 | PTGDR2 (0.42) | PTGDR2GCGRGIPRSCN9ACACNA1B | |
| SCHEMBL18974390 | 0.90 | SCN9A (0.41) | SCN9ASTSCYP19A1 | |
| SCHEMBL18974397 | 0.89 | GCGR (0.40) | GCGRGIPRSCN9A | |
| SCHEMBL18974407 | 0.89 | SCN9A (0.39) | GCGRGIPRSCN9ACACNA1BCACNA1H | |
| SCHEMBL18974387 | 0.88 | NSD2 (0.40) | PTGDR2SCN9A | |
| SCHEMBL18974389 | 0.88 | POLB (0.40) | GCGRGIPRSCN9A | |
| SCHEMBL18974402 | 0.87 | SCN9A (0.37) | SCN9A | |
| SCHEMBL18974513 | 0.86 | NR3C2 (0.39) | PTGDR2SCN9ACCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3388425-B1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| EP-3388425-B1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-10689354-B2 | Aminoazole derivative | TEIJIN PHARMA LIMITED (JP) | 2020-06-23 | — | — | US | disclosed |
| US-10689354-B2 | Aminoazole derivative | TEIJIN PHARMA LIMITED (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20190031628-A1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
| US-20190031628-A1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
| EP-3388425-A1 | AMINOAZOLE DERIVATIVE | Teijin Pharma Limited (JP) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017099237-A1 | AMINOAZOLE DERIVATIVE | 帝人ファーマ株式会社 | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689354-B2 | Aminoazole derivative | AR, NR3C2, NR5A1 | PTGDR2 1554/4885GCGR 119/4885GIPR 560/4885 |
| US-20190031628-A1 | AMINOAZOLE DERIVATIVE | AR, NR3C2, NR5A1 | PTGDR2 1554/4885GCGR 119/4885GIPR 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.